OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Oliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 10
Oliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 10
Showing 10 citing articles:
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel
Wael Al Mahmeed, Khalid Al‐Rasadi, Yajnavalka Banerjee, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 45
Wael Al Mahmeed, Khalid Al‐Rasadi, Yajnavalka Banerjee, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 45
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Jaime P. Almandoz, Lisa Anderson, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Oliver Schnell, Jaime P. Almandoz, Lisa Anderson, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care
Stephan Jacob, Andrew J. Krentz, John Deanfield, et al.
Drugs (2021) Vol. 81, Iss. 12, pp. 1373-1379
Closed Access | Times Cited: 19
Stephan Jacob, Andrew J. Krentz, John Deanfield, et al.
Drugs (2021) Vol. 81, Iss. 12, pp. 1373-1379
Closed Access | Times Cited: 19
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
Maximilian Brockmeyer, Claudio Parco, Kris Gregory Vargas, et al.
Journal of Nephrology (2024) Vol. 37, Iss. 2, pp. 309-321
Open Access | Times Cited: 2
Maximilian Brockmeyer, Claudio Parco, Kris Gregory Vargas, et al.
Journal of Nephrology (2024) Vol. 37, Iss. 2, pp. 309-321
Open Access | Times Cited: 2
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs
A Buzea, Peter Manu, Lorena Dima, et al.
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 11, pp. 729-744
Closed Access | Times Cited: 4
A Buzea, Peter Manu, Lorena Dima, et al.
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 11, pp. 729-744
Closed Access | Times Cited: 4
The potential of precision diabetology for type 2 diabetes treatment—evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials
Oliver Kuß, Michael Roden, Sabrina Schlesinger, et al.
Acta Diabetologica (2024)
Open Access
Oliver Kuß, Michael Roden, Sabrina Schlesinger, et al.
Acta Diabetologica (2024)
Open Access
Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes
Manfredi Rizzo, Francesco Cosentino, Christos S. Mantzoros
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 7, pp. 795-797
Open Access | Times Cited: 1
Manfredi Rizzo, Francesco Cosentino, Christos S. Mantzoros
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 7, pp. 795-797
Open Access | Times Cited: 1
Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review
Viswanathan Mohan, SUBHASH KUMAR WANGNOO, Sambit Das, et al.
World Journal of Diabetes (2022) Vol. 13, Iss. 12, pp. 1168-1183
Open Access | Times Cited: 1
Viswanathan Mohan, SUBHASH KUMAR WANGNOO, Sambit Das, et al.
World Journal of Diabetes (2022) Vol. 13, Iss. 12, pp. 1168-1183
Open Access | Times Cited: 1
